Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials

Elizabeth M. Brunt, David E. Kleiner, Laura A. Wilson, Arun J. Sanyal, Brent A. Neuschwander‐Tetri, for the Nonalcoholic Steatohepatitis Clinical Research Network – 14 December 2018 – Hepatocellular injury and inflammation are believed to be the primary drivers of fibrogenesis that ultimately lead to cirrhosis in patients with nonalcoholic steatohepatitis (NASH).

Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection

Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.

Recurrence of Hereditary Hemorrhagic Telangiectasia After Liver Transplantation: Clinical Implications and Physiopathological Insights

Jérôme Dumortier, Sophie Dupuis‐Girod, Pierre‐Jean Valette, Alexander Valent, Olivier Guillaud, Jean‐Christophe Saurin, Valérie Hervieu, Philip Robinson, Henri Plauchu, Pierre Paliard, Olivier Boillot, Jean‐Yves Scoazec – 14 December 2018 – Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. We provide a long‐term evaluation of graft status after LT for HHT, with a focus on the risk of recurrence.

Subscribe to